Mean ± SD | ||
---|---|---|
Control group (n = 23) | Diabetic group (n = 30) | |
Sex (male/female) | 5/18 | 17/13 |
Age (year) | 43.5 ± 16.5 | 68.5 ± 7.4 |
Height (cm) | 165.2 ± 11.3 | 160.7 ± 8.4 |
Weight (kg) | 60.9 ± 15.0 | 62.6 ± 13.4 |
BMI (kg/m2) | 22.0 ± 3.3 | 24.1 ± 3.9 |
SBP (mmHg) | 116.2 ± 11.5 | 134.8 ± 17.0 |
DBP (mmHg) | 69.1 ± 9.1 | 73.5 ± 9.0 |
Duration of diabetes (year) | 14.7 ± 11.5 | |
HbA1c (%) | 6.7 ± 0.6 | |
Creatinine (mg/dl) | 0.87 ± 0.26 | |
eGFR (mL/min/1.73 m2) | 63.5 ± 14.8 | |
Neuropathy, n (%) | 8 (26.7) | |
Retinopathy, n (%) | 3 (10.0) | |
Nephropathy, n (%) | 6 (20.0) | |
Anti-diabetes treatment | ||
Diet only, n (%) | 1 (3.0) | |
SU, n (%) | 0 (0) | |
Glinide, n (%) | 2 (6.7) | |
DPP-4 inhibitor, n (%) | 21 (70.0) | |
Biguanide, n (%) | 15 (50.0) | |
Thiazolidine, n (%) | 5 (16.7) | |
SGLT-2 inhibitor, n (%) | 7 (23.3) | |
α-glucose inhibitor, n (%) | 7 (23.3) | |
GLP-1 receptor, n (%) | 3 (10.0) | |
Insulin, n (%) | 6 (20.0) |